Shareholding for the Period Ended June 30, 2016
Glenmark Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2016. For more details, kindly Click here21-07-2016
21-07-2016
Buy Glenmark Pharmaceuticals Ltd., target Rs 902: Siddarth Bhamre
Buy Glenmark Pharmaceuticals Ltd. with a target of Rs 902 and a stop loss of Rs 82821-07-2016
Glenmark Pharmaceuticals receives ANDA approval for Rosuvastatin Calcium Tablets, 5 mg (base), 10 mg (base), 20 mg (base), and 40 mg (base)
Glenmark Pharmaceuticals Ltd has informed BSE regarding a Press Release dated July 20, 2016, titled "Glenmark Pharmaceuticals receives ANDA approval for Rosuvastatin Calcium Tablets, 5 mg (base), 10 mg (base), 20 mg (base), and 40 mg (base)".20-07-2016
AGM on August 12, 2016
Glenmark Pharmaceuticals Ltd has informed BSE that the 38th Annual General Meeting (AGM) of the Company will be held on August 12, 2016.19-07-2016
Fixes Book Closure for Dividend & AGM
Glenmark Pharmaceuticals Ltd has informed BSE that the Register of Members & Share Transfer Books of the Company will remain closed from August 05, 2016 to August 12, 2016 (both days inclusive) for the purpose of Payment of Dividend & 38th Annual General Meeting (AGM) of the Company to be held on August 12, 2016.The Dividend, if approved by the shareholders at the ensuing Annual General Meeting will be paid on or before August 31, 2016.19-07-2016
Sell Glenmark Pharmaceuticals Ltd., target Rs 820 Dr CK Narayan
Sell Glenmark Pharmaceuticals Ltd. at a price target of Rs 820 and a stop loss at Rs 845.19-07-2016
Investor Presentation
Glenmark Pharmaceuticals Ltd has submitted to BSE a copy of Investor Presentation19-07-2016
Glenmark Pharma looks to raise $200 million to repay debt
"Glenmark Pharmaceuticals Ltd has decided to tap into the International Bond market and is planning to raise around USD 200 mn by issuing USD denominated non-convertible unsecured bonds," the company said in a BSE filing.18-07-2016
Glenmark Pharmaceuticals Limited plans to issue a USD denominated Reg S International Bond for repaying its existing debt
Glenmark Pharmaceuticals Ltd has informed BSE that subsequent to the rating received by the leading credit agencies in the world i.e. S&P; and Fitch, Glenmark Pharmaceuticals limited has decided to tap into the International Bond market and is planning to raise around USD 200 mn by issuing USD denominated non-convertible unsecured bonds. The net proceeds will be used for repaying the existing debt. These bonds are planned to be listed on the Singapore...18-07-2016
Glenmark expects cash surge from license deals in next 18 months
Glenmark has already managed to glean $200 million from licensing deals around the intellectual property15-07-2016